title: New class PCSK9 blockers stride into cholesterol market.
authors.forename: Cormac
authors.initials: C
authors.lastname: Sheridan
mesh_terms: D000924:Anticholesteremic Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood*; D004345:Drug Industry; D006801:Humans; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases
chemical_list: D000924:Anticholesteremic Agents; D002784:Cholesterol; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases